Zusammenfassung
Die nephrogene systemische Fibrose ist ein erstmals im Jahr 2000 beschriebenes neues Krankheitsbild bei niereninsuffizienten Patienten, das durch eine Fibrosierung von Dermis und viszeralen Organen charakterisiert ist. Vor kurzem konnte die Ätiologie dieser Erkrankung entschlüsselt werden. Der Einsatz Gadolinium-haltiger Kontrastmittel bei der Magnetresonanztomographie kann bei eingeschränkter Nierenfunktion zu einer Ablagerung des Gadoliniums im Gewebe und zur Auslösung eines Fibroseprozesses führen. Zahlreiche Publikationen der letzten Monate unterstützen diese Hypothese und haben zu aktuellen Empfehlungen der Gesundheitsbehörden für einen restriktiven Gebrauch von Gadolinium bei niereninsuffizienten Patienten geführt.
Abstract
Nephrogenic systemic fibrosis is a new disease entity which was first described in 2000. It is characterized by dermal and visceral fibrosis in patients with impaired renal function. Recently, the etiology of this disease has been unveiled. The application of gadolinium-containing contrast media in patients with decreased renal function can lead to gadolinium deposition in various tissues which induces the fibrotic process. Numerous publications within the last few months have supported this hypothesis and have led to recommendations by the health authorities to carefully weigh the benefits and risks of using gadolinium in patients with impaired renal function.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Boyd AS, Zic JA, Abraham JL (2007) Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56: 27–30
Broome DR, Girguis MS, Baron PW et al. (2007) Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. Am J Radiol 188: 586–592
Centers for Disease Control and Prevention (2007) Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents – St. Louis, Missouri, 2002–2006. MMWR Morb Mortal Wkly Rep 56: 137–141
Chewning RH, Murphy KJ (2007) Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with real insufficiency. J Vasc Interv Radiol 18: 331–334
Cowper SE, Bucala R, Leboit PE (2006) Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis – Setting the record straight. Semin Arthritis Rheum 35: 208–210
Cowper SE, Robin HS, Steinberg SM et al. (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356: 1000–1001
Cowper SE, LD Su, Bhawan J et al. (2001) Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23: 383–393
Cowper SE (2003) Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 15: 785–790
Fazeli A, Lio PA, Liu V (2004) Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link? Arch Dermatol 140: 1401
Galan A, Cowper SE, Bucala R (2006) Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheum 18: 614–617
Grobner T (2006) Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21: 1104–1108
High WA, Ayers RA, Chandler J et al. (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56: 21–26
High WA, Eng M, Ayers RA, Cowper SE (2007) Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56: 710–712
Jimenez SA, Artlett CM, Sandorfi N et al. (2004) Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Arthritis Rheum 50: 2660–2666
Khurana A, Runge VM, Narayanan M et al. (2007) Nephrogenic systemic fibrosis. A review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 42: 139–145
Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE (2007) Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 242: 647–649
LeBoit PE (2003) What nephrogenic fibrosing dermopathy might be. Arch Dermatol 139: 928–930
Mackay-Wiggan JM, Cohen DJ, Hardy MA et al. (2003) Nephrogenic fibrosing dermophathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 38: 55–60
Maloo M, Abt P, Kashyap et al. (2006) Nephrogenic systemic fibrosis among liver transplant recipients: A single institution experience and topic update. Am J Transplant 6: 2212–2217
Marckmann P, Skov L, Rossen K et al. (2006) Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17: 2359–2362
Mendoza FA, Artlett CM, Sandorfi N et al. (2006) Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35: 238–249
Morcos SK (2007) Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 80: 73–76
Obermoser G, Emberger M, Wieser M et al. (2004) Nephrogenic fibrosing dermopathy in two patients with systemic lupus erythematosus. Lupus 13: 609–612
Sadowski EA, Bennett LK, Chan MR et al. (2007) Nephrogenic systemic fibrosis: Risk factors and incidence estimation. Radiology 243: 148–157
Swaminathan S, Ahmed I, McCarthy JT et al. (2006) Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 146: 229–230
Thomsen HS (2006) Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 16: 2619–2621
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Manger, B. Nephrogene systemische Fibrose. Z. Rheumatol. 66, 533–535 (2007). https://doi.org/10.1007/s00393-007-0186-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-007-0186-0